Skip to content

Clinical trials

Postoperative Complications trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Postoperative Complications Country / region: United States Clear all

153 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20013
20034
20042
20056
20065
20078
20084
20092
20104
20114
20127
20136
20145
20159
20168
201710
20189
20199
20207
20218
20227
20234
20247
20259
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed91
Recruiting22
Terminated18
Withdrawn6
Active, not recruiting6
Unknown status5
Enrolling by invitation3
Suspended1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Mayo Clinic6
The Cleveland Clinic6
University of California, San Francisco6
Wake Forest University Health Sciences4
Beth Israel Deaconess Medical Center3
Duke University3
University of Alabama at Birmingham3
University of California, Irvine3
University of Chicago3
University of Pittsburgh3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Postoperative Complications153
Postoperative Pain15
Pain7
Delirium6
Postoperative Cognitive Complications6
Intraoperative Complications5
Surgical Wound Infection5
Atrial Fibrillation4
Breast Neoplasms4
Cognitive Dysfunction4

Trials

Showing 1 to 25 of 153. Each trial links to its page on Pharma Observatory.

53 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.